Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanostructured Lipid Carriers for Drug Delivery Systems
share announcement

Nanostructured Lipid Carriers for Drug Delivery Systems

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (10 December 2023) | Viewed by 1774

Special Issue Editors

Dr. Violeta Rodriguez-Ruiz

E-Mail Website
Guest Editor
ERRMECe Laboratory, Biomaterials for Health Group, CY Cergy Paris Université, Maison Internationale de la Recherche, I MAT, 1 Rue Descartes, 95031 Neuville sur Oise, France
Interests: natural bioactive compounds; nanotechnologies for drug delivery; biomaterials
Dr. Graciela Pavon-Djavid

E-Mail Website
Guest Editor
Laboratory for Vascular Translational Science, Cardiovascular Bioengineering, Université Sorbonne Paris Nord - INSERM U1148, 99 Av. Jean-Baptiste Clément, 93430 Villetaneuse, France
Interests: nanotechnology; lipid formulations; drug delivery; drug targeting; cellular models; animal models; oxidative stress; antioxidants
Special Issues, Collections and Topics in MDPI journals
Dr. Virginie Gueguen

E-Mail Website
Guest Editor
Laboratory for Vascular Translational Science, Paris, France
Interests: physico-chemical analysis; drug delivery; diffusion

Special Issue Information

Dear Colleagues,

Lipid nanoparticles have shown rapid progress and have had an immense impact on the treatment of pathologies such cancer, diabetes, and infections and have also been used in vaccines. Specifically, nanostructured lipid carriers (NLCs) are composed of a mixture of solid and liquid lipids that have been stabilized in the aqueous phase using surfactants. Their biocompatible composition ensures the development of safe drug delivery systems. They are industrially interesting due to their physicochemical stability and scalability. NLCs have attracted increasing amounts of attention in recent years for the delivery of drugs, nucleic acids, proteins, peptides, nutraceuticals, and cosmetics.

This Special Issue aims to highlight recent research on the development of novel NLC-based pharmaceutical formulations to allow readers a holistic overview of the latest progress in the field of nanostructured lipid carriers.

Original research and review articles on the following topics related to NLCs are recommended: the synergistic effects of active ingredients and biomaterials, targeting, controlled release, adsorption/diffusion, and biological and clinical studies.

Dr. Violeta Rodriguez-Ruiz
Dr. Graciela Pavon-Djavid
Dr. Virginie Gueguen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • innovative NLC formulations
  • physico-chemical evaluations
  • diffusion studies
  • preservation of the biological activity: oral administration
  • dermal administration
  • animal models
  • NLC /biomaterial combinations
  • biomodelling
  • synergistic active ingredients

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 7976 KiB  
Article
Novel Bovine Serum Albumin-Decorated–Nanostructured Lipid Carriers Able to Modulate Apoptosis and Cell-Cycle Response in Ovarian, Breast, and Colon Tumoral Cells
by Robert Tincu, Mirela Mihaila, Marinela Bostan, Florina Teodorescu, Daniela Istrati, Nicoleta Badea and Ioana Lacatusu
Pharmaceutics 2023, 15(4), 1125; https://doi.org/10.3390/pharmaceutics15041125 - 02 Apr 2023
Cited by 1 | Viewed by 1411
Abstract
A novel nanoscale approach was developed for the improved cellular internalization of hybrid bovine serum albumin–lipid nanocarriers loaded with piperine (NLC-Pip–BSA) in different tumor cells. The effect of the BSA-targeted–NLC-Pip and untargeted-NLC-Pip on the viability, proliferation, and levels of cell-cycle damage and apoptosis [...] Read more.
A novel nanoscale approach was developed for the improved cellular internalization of hybrid bovine serum albumin–lipid nanocarriers loaded with piperine (NLC-Pip–BSA) in different tumor cells. The effect of the BSA-targeted–NLC-Pip and untargeted-NLC-Pip on the viability, proliferation, and levels of cell-cycle damage and apoptosis in the colon (LoVo), ovarian (SKOV3) and breast (MCF7) adenocarcinoma cell lines was comparatively discussed. NLCs were characterized concerning particle size, morphology, zeta potential, phytochemical encapsulation efficiency, ATR-FTIR, and fluorescence spectroscopy. The results showed that NLC-Pip–BSA showed a mean size below 140 nm, a zeta potential of −60 mV, and an entrapment efficiency of 81.94% for NLC-Pip and 80.45% for NLC-Pip–BSA. Fluorescence spectroscopy confirmed the coating of the NLC with the albumin. By MTS and RTCA assays, NLC-Pip–BSA showed a more pronounced response against the LoVo colon cell line and MCF-7 breast tumor cell lines than against the ovarian SKOV-3 cell line. Flow cytometry assay demonstrated that the targeted NLC-Pip had more cytotoxicity and improved apoptosis than the untargeted ones in MCF-7 tumor cells (p < 0.05). NLC-Pip caused a significant increase in MCF-7 breast tumor cell apoptosis of ~8X, while NLC-Pip–BSA has shown an 11-fold increase in apoptosis. Full article
(This article belongs to the Special Issue Nanostructured Lipid Carriers for Drug Delivery Systems)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop